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Background: We wished to evaluate the impact of S-1 combined with oxaliplatin (SOX regimen) as neoadjuvant
chemotherapy on surgical outcomes after gastrectomy with D2 lymphadenectomy.
Methods: From February 2012 to September 2013, 170 patients with American Joint Committee on Cancer (AJCC)
stage II–III gastric cancer were assessed retrospectively. Eighty patients underwent neoadjuvant chemotherapy
before radical gastrectomy, and 90 patients received surgical treatment with adjuvant chemotherapy. Patients received
S-1 (80 mg/m2/day; days 1–14) and oxaliplatin (130 mg/m2; day 1) as neoadjuvant or adjuvant chemotherapy, and this
schedule was repeated every 3 weeks. Gastrectomy with D2 lymphadenectomy was standard therapy for each patient.
Surgical outcomes between the two groups were analyzed statistically.
Results: There was no significant difference in the total prevalence of complications between neoadjuvant and
adjuvant groups (18.8% vs. 22.2%, P = 0.704). The most common postoperative complications were surgical site infection
(6.5%) and gastrointestinal motility disorders (3.5%). The clinical response rate was 68.8%, and ten patients (12.5%) had a
pathological complete response after neoadjuvant chemotherapy. The SOX regimen as neoadjuvant chemotherapy for
AJCC stage II/III gastric cancer can be effective without increasing the risk of postoperative complications.
Conclusions: The SOX regimen could be a neoadjuvant chemotherapy for advanced gastric cancer worldwide in
the future.
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Gastric cancer (GC) is the second leading cause of all can-
cer deaths worldwide [1,2] and a frequently diagnosed car-
cinoma in East Asia, Eastern Europe, and parts of South
America [2-4]. For locally advanced GC, gastrectomy with
D2 lymphadenectomy combined with adjuvant chemother-
apy is the first-line treatment in Asia. S-1 (TS-1/Teysuno™)
monotherapy for 1 year is used widely postoperatively in
Japan [5]. However, this regimen is more appropriate for
stage II disease rather than stage III disease [6]. Also,
single-agent chemotherapy cannot be employed to treat
advanced GC as standard chemotherapy [7]. Therefore, a* Correspondence: litbj301@vip.sina.com
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based on S-1 needs to be developed for stage II or III pa-
tients in Asia. In contrast, other approaches have been
established in Europe [8,9] and the United States [10].
Doublet chemotherapy using S-1 and cisplatin (SP) is
the standard regimen for stage IV GC in Japan [11].
However, for locally advanced disease, cisplatin cannot
be given during the first course of adjuvant chemother-
apy after D2 surgery because grade 3 or 4 toxicities are
observed quite frequently [12]. According to studies on
chemotherapeutic drugs, it is shown that oxaliplatin is
less toxic than cisplatin [13] and the S-1 plus oxaliplatin
(SOX) regimen is not inferior to SP with regard to
progression-free survival [14]. Therefore, the SOX regi-
men could be a novel option for locally advanced GC.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vival benefits for adjuvant chemotherapy, but periopera-
tive chemotherapy was conducted in the MRC Adjuvant
Gastric Infusional Chemotherapy (MAGIC) trial in the
UK [8]. Owing to such positive results, neoadjuvant
chemotherapy for locally advanced GC became a grade
A recommendation in the guidelines for the manage-
ment of GC by the National Comprehensive Cancer
Network. Neoadjuvant chemotherapy has been accepted
in some countries, but the optimal regimen has yet to be
determined. Some patients cannot tolerate the toxicities
induced by doublet or triplet chemotherapeutic drugs
such as SP or ECF regimen after surgery. To increase
the number of patients who complete treatment proto-
cols for locally advanced GC, the SOX regimen should
be preferred to the SP regimen because the former is
less toxic and the efficacy of the two regimens should be
identical.
Of course, adverse effects need to be considered, but
postoperative complications cannot be ignored. The
SOX regimen has low toxicity, but patients may not be
able to undergo postoperative chemotherapy because of
poor status induced by surgical complications. There-
fore, to prove the safety of neoadjuvant chemotherapy
with the SOX regimen, the morbidity and mortality after
D2 surgery must be assessed.
The SOX regimen is as effective as cisplatin plus S-1
with favorable safety profile and is widely used for unre-
sectable gastric cancer in Asia [15-17]. However, as for
the SOX regimen, there is no randomized controlled
trial (RCT) published for resectable gastric cancer. Thus,
this protocol is a novel and potential treatment to prove
the efficacy and safety for stage II and III gastric cancer.
In China, the SOX regimen is one of the first-line
treatments for advanced GC [15]. The RCT on the SOX
regimen neoadjuvantly is ongoing in our center [18].
Some specialized hospitals have participated in this pro-
gram in China. However, the efficacy and safety of the
SOX regimen in a neoadjuvant setting have not been
well established. Here, we wished to assess the tumor
responses and postoperative morbidity for patients
receiving perioperative SOX chemotherapy compared
with adjuvant chemotherapy.
The objective of this study is to determine whether
neoadjuvant chemotherapy with the SOX regimen in
stage II and III patients could make radical surgery
feasible and improve the prognosis.
Methods
Ethical approval of the study protocol
The study protocol was approved by the Ethics Committee
of the Chinese PLA General Hospital (Beijing, China). All
patients provided informed consent for the procedure in
the study.Study design
Gastric carcinoma was diagnosed by endoscopy and
biopsy. Endoscopic ultrasound (EUS) and enhanced CT
scan were operated for clinical T and N stages. Diagnos-
tic laparoscopy and lavage cytology were performed to
exclude peritoneal metastasis. After clinical staging,
stage II or III patients were selected and assigned to two
groups based on their preference. Group A received two-
cycle SOX regimen and evaluated by Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1. If the assessment
is complete response (CR) or partial response (PR), the
patients should be given another one or two cycles. If the
assessment is stable disease (SD) or progressive disease
(PD), the surgery need be performed directly. In group B,
surgery should be operated immediately. After surgery,
tumor staging, pathological results, R0 resection, and
complications were evaluated to prove the efficacy and
safety of the SOX regimen as neoadjuvant chemotherapy
(Figure 1).
Patients
This retrospective study initially consisted of 201 patients
with GC who underwent resection from the Chinese PLA
General Hospital from February 2012 to September 2013.
All the clinicopathological information was available, in-
cluding demographic data, patients’ comorbidities, surgical
parameters, image study information, pathological diagno-
sis, perioperative therapies, tumor response, and follow-up
data. Among these patients with GC, only those who had
stage II–III GC and D2 lymphadenectomy were enrolled
into the study. Patients who had D0 or D1 resection, para-
aortic lymph node involvement, Virchow lymph node
metastasis, and incomplete neoadjuvant chemotherapy
were excluded because this study mainly focused on those
patients under D2 resection. Finally, 170 patients were
enrolled into this study.
Of these 170 individuals, 80 patients received SOX
neoadjuvant chemotherapy and 90 patients received surgi-
cal treatment with adjuvant chemotherapy. Patients had
been proven to have GC by histological analyses. Subjects
had been assessed clinically as being T2–4, N0–3, and M0
according to the third English edition of the Japanese
Classification of Gastric Carcinoma [19], and tumor size
measured according to RECIST v1.1 [20]. Additional eligi-
bility criteria comprised no distant/peritoneal metastases
and negative cytology by contrast-enhanced computed
tomography (CE-CT) and laparoscopy, as well as Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) of 0 or 1. Patients had not received chemotherapy or
radiotherapy previously. The clinical diagnosis of T and N
stages was based mainly on EUS and CE-CT. Diagnostic
laparoscopy and lavage cytology were used to exclude
peritoneal metastasis by following the method of Yano
et al. [21]. In order to improve the accuracy of clinical
Figure 1 Study design.
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ation. Therefore, all patients were clinically diagnosed as
stage II or III based on ultrasonic endoscopy, CE-CT scan,
and staging laparoscopy. Patients were assigned to each
arm of the study based on their preference after detailedexplanation of the advantages and disadvantages of the
two regimens. Meanwhile, patients provided informed
consent to receive the corresponding treatment. After the
treatment protocols, the data were analyzed and summa-
rized following these 170 cases retrospectively. Patients
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undergo D2 resection were excluded from the study. D2
surgery was the standard treatment in Asia. To prolong
the overall survival, we performed D2 surgery routinely. If
patients had severe cardiac disease, significant cerebro-
vascular illness, or pregnancy, the treatment protocol can-
not be used. Similarly, patients with another diagnosed
malignancy in recent 5 years were precluded. Therefore,
170 patients that meet study criteria during the stated
time period were included (Additional files 1 and 2).
Preoperative chemotherapy
S-1 was administered via the oral route twice a day for a
total of 80 mg/m2 from day 1 to day 14, and oxaliplatin
was given as an intravenous infusion of 130 mg/m2 on
day 1. This regimen was repeated every 3 weeks for two
to four cycles. Blood tests were carried out, blood
biochemistry assessed, levels of tumor markers [carci-
noembryonic antigen (CEA), cancer antigen (CA) 19–9]
measured, physical examination undertaken, and PS
checked <1 week before the initiation of chemotherapy.
Blood tests were carried out, symptoms evaluated, and
physical examination carried out each week during
treatment. The regimen was modified by decreasing S-1
from 120 to 100 or 80 mg/day, and oxaliplatin from 130
to 100 or 85 mg/m2 if patients had a white blood cell
(WBC) count ≤4,000/mm3, platelet count ≤10,000/
mm3, abnormal feelings in peripheral nerves, diarrhea,
or nausea of grade ≥2. If adverse events worsened, the
regimen was postponed until recovery. After two cycles
of chemotherapy, tumor response was evaluated based
on the findings of CE-CT and EUS according to RECIST
1.1 [20]. If tumors had increased in size, resection was
carried out immediately. If not, one or two additional
cycles of chemotherapy were given before D2 surgery.
Surgery and postoperative chemotherapy
Patients underwent surgical resection within 6 weeks
after completion of SOX neoadjuvant chemotherapy. For
all patients, gastrectomy with D2 lymphadenectomy was
conducted by experienced surgeons according to criteria
set by the Japanese Gastric Cancer Association [19].
Intraperitoneal wash cytology was carried out at the
beginning of each surgical procedure. Based on the
location of the primary tumor, distal, proximal, or total
gastrectomy was carried out. In the neoadjuvant chemo-
therapy group, patients underwent four to six cycles of
chemotherapy with the SOX regimen after surgery.
Patients in the other group received eight cycles of
adjuvant chemotherapy with the SOX regimen.
Complications
Complications were recorded prospectively for each pa-
tient after surgery. Surgery-related complications includedsurgical site infection, postoperative hemorrhage, anasto-
motic leakage, ileus or bowel obstruction, wound dehis-
cence, biliary fistulae, and lymphatic fistulae. Non-surgical
complications were gastrointestinal motility disorders or
gastroplegia, pulmonary infection, thrombocytopenia,
catheter-related sepsis, thrombosis, and renal dysfunction.
Pathological assessment
Resection specimens were examined by the same experi-
enced pathologist. Postoperative pathology was reported
as follows: (i) Lauren pathological classification for primary
tumors; (ii) histologic response was assessed according to
the proportion of tumor affected by degeneration or necro-
sis [19]; (iii) resection margins were classified as R0 (no
cancer at the resection margin), R1 (microscopically in-
volved margin), and R2 (macroscopically involved margin);
and (iv) positive and negative lymph nodes in each group.
Statistical analyses
Data were collected and supervised by the same surgeon.
Results are the median or means for continuous variables
depending on the one-sample Kolmogorov-Smirnov test
(by which normal distribution was determined). Propor-
tions are expressed as qualitative variables. Means, me-
dian, and proportions between the two groups were
compared using the Student’s t test, Mann–Whitney U
test, or Pearson chi-square test. Relative analysis was
performed by ordinal multinomial logistic regression.
P ≤ 0.05 (two-sided) was considered significant. Statis-




One-hundred and seventy patients were assigned to the
neoadjuvant group (n = 80) or adjuvant group (n = 90).
The median age of the study cohort was 60 years (range,
21–82). The two groups were similar in terms of age,
sex, and body mass index (BMI). The distribution was
also well balanced with respect to tumor location and
clinical TNM staging (Table 1). The PS of patients in the
two groups according to the ECOG was 0 or 1.
Efficacy of neoadjuvant treatment
Patients in the neoadjuvant group received at least two
cycles of preoperative SOX chemotherapy. Thirteen
(16.3%), 18 (22.5%), and 49 patients (61.3%) received
two, three, and four cycles, respectively. Ten American
Joint Committee on Cancer (AJCC) II–III patients
(12.5%) achieved a CR, and 45 patients (56.3%) received
a PR. Twenty-three patients (28.7%) had SD and two
patients (2.5%) suffered from PD, resulting in an overall
response rate (RR) of 68.8% [95% confidence interval
(CI) 0.58–0.79] and disease control rate of 97.5% (95%
Table 1 Patient characteristics
Neoadjuvant (n = 80) Adjuvant (n = 90) P
Age (years) 60 (21–74) 59 (29–82) 0.762
Sex 0.982
Male 63 (78.8%) 71 (78.9%)
Female 17 (21.2%) 19 (21.1%)
BMI (kg/m2) 23.8 23.6 0.709
> 25 26 (32.5%) 29 (32.2%)
Tumor location 0.135
GEJ 32 (40.0%) 21 (23.3%)
Body 15 (18.8%) 22 (24.5%)
Distal 32 (40.0%) 45 (50.0%)
Total 1 (1.2%) 2 (2.2%)
Clinical TNM stage 0.172
II 4 10
III 76 80
BMI body mass index, GEJ gastroesophageal junction.
Table 3 Relative analysis on clinical responses
No. CR PR SD PD P
GEJ 32 4 20 7 1
Body 15 1 9 5 0 0.543
Distal 32 5 15 11 1 0.504
Total 1 0 1 0 0 0.845
GEJ gastroesophageal junction, CR complete response, PR partial response,
SD stable disease, PD progressive disease.






White blood cells 4.73 5.63 <0.001
Platelets 156.7 240.4 <0.001
Hemoglobin 125.1 121.5 0.291
Serum albumin 39.4 38.9 0.520
CEA >5 μg/L 17 (21.8%) 14 (16.3%) 0.427
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adjuvant chemotherapy were well tolerated and manage-
able in all cases.
The results of the responses in the NAC group associ-
ated with tumor locations in the stomach are summa-
rized in Table 3. However, the clinical responses were
irrelevant to tumor locations by ordinal multinomial lo-
gistic regression (P = 0.873).
Preoperative status
WBC counts and platelet counts were lower in the neo-
adjuvant group than in the adjuvant group (P < 0.001).
This result was in accordance with the most common
grade 3/4 toxicities (neutropenia and thrombocytopenia)
observed in the SOX regimen [14]. CEA or CA 19–9
represents a strong prognostic factor for GC (especially
in patients with high preoperative levels of these
markers), so measurement of these tumor markers be-
fore surgery was essential [22]. There was no significant
difference in preoperative levels of CEA and CA 19–9Table 2 Clinical response after SOX neoadjuvant
chemotherapy





Overall response rate 55 68.8 (58.6–79.0)
Disease control rate 78 97.5 (94.1–100)
CI confidence interval, CR complete response, PR partial response, SD stable
disease, PD progressive disease. Disease control rate = CR + PR + SD.between the two groups. Before the neoadjuvant chemo-
therapy, the median maximum diameter of tumors
observed by EUS was similar in both groups (5 vs. 5 cm,
P = 0.329). Both groups were well balanced in terms of
hemoglobin levels, serum levels of albumin, comorbidity,
and tumor size (Table 4).
Operative details
The mean duration of surgery was 230 min in the neo-
adjuvant group and 212 min in the adjuvant group (P =
0.017). As a result of hemorrhage or tissue edema in-
duced by neoadjuvant chemotherapy, the operative time
was increased to ensure careful resection. The median
operative blood loss in the neoadjuvant group was
300 mL (range, 100–700), which was significantly differ-
ent from that of the adjuvant group (P = 0.05). The vol-
ume of blood loss during the operation was much lower
in the adjuvant group. In the neoadjuvant group, four
patients (5%) were transferred to the intensive care unit
and 12 (15%) received a blood transfusion during sur-
gery. There was no difference in terms of type of resec-
tion or reconstruction (Table 5). D2 lymphadenectomyCA 19–9 > 37 μg/mL 13 (16.7%) 16 (18.6%) 0.839
Comorbidity 43 (53.8%) 54 (60.0%) 0.441
Cardiovascular 31 (38.8%) 28 (31.1%) 0.335
Pulmonary 3 (3.8%) 5 (5.6%) 0.724
Diabetes mellitus 2 (2.5%) 9 (10.0%) 0.062
Gastrointestinal disease 7 (8.8%) 4 (4.4%) 0.352
Urinary 4 (5.0%) 1 (1.1%) 0.189
Liver 4 (5.0%) 8 (8.9%) 0.381
History of surgery 22 (27.5%) 21 (23.3%) 0.597
Other 12 (15.0%) 20 (22.2%) 0.245
CA 19–9 cancer antigen 19–9, CEA carcinoembryonic antigen.






Total operative time 230.4 212.2 0.017
Operative blood loss (mL) 300 200 0.050
≥ 200 66 (83.5%) 60 (66.7%) 0.014
Procedure 0.320b
Total gastrectomy 23 (28.8%) 30 (33.3%) 0.249c
Roux-en-Y 23 (100.0%) 27 (90.0%)
Braun 0 (0%) 3 (10.0%)
Distal gastrectomy 33 (41.2%) 42 (46.7%) 0.425d
Billroth I 26 (78.8%) 28 (66.7%)
Billroth II 2 (6.1%) 6 (14.3%)
Roux-en-Y 5 (15.1%) 8 (19.0%)
Proximal gastrectomy 24 (30.0%) 18 (20.0%) —
Esophagogastric anastomosis 24 (100.0%) 18 (100.0%)
Extent of resection 0.872
R0 76 (95.0%) 85 (94.4%)
R1/R2 4 (5.0%) 5 (5.6%)
Mean no. of nodes removed 29 30 0.317
aChi-square test; bcomparison of total, distal, and proximal gastrectomies;
ccomparison of Roux-en-Y and Braun; dcomparison of Billroth I, Billroth II,
and Roux-en-Y.
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vested lymph nodes in the two groups was not signifi-
cantly different (29 vs. 30, P = 0.317). Splenectomy was
carried out in three patients (3.3%) in the adjuvant
group. Resection was curative in 76 patients (95.0%) in
the neoadjuvant group compared with 85 subjects
(94.4%) who received adjuvant chemotherapy after sur-
gery (P = 0.872).Pathological findings
The median maximum diameter of tumors obtained from
pathological specimens was smaller in the neoadjuvant
group than in the adjuvant group (2.5 vs. 5 cm, P < 0.001),
a finding in accordance with tumor shrinkage induced by
preoperative chemotherapy. Ten patients (12.5%) had a
pathological complete response (pCR), whereas two other
patients in the neoadjuvant group were evaluated as
ypT0N1M0. Before the neoadjuvant chemotherapy, the
clinical T staging was not significantly different in both
groups (P = 0.323). After the surgical resections, the patho-
logical results showed that there was a smaller proportion
of stage T3 and T4 tumors in the neoadjuvant group than
in the adjuvant group (43.8% vs. 90.0%, P < 0.001). Fifty-six
patients (70%) had tumor downstaging. An obvious trend
of less metastasis of lymph nodes in the neoadjuvant group
than in the adjuvant group was noted (58.8% vs. 14.4%,
P < 0.001) (Table 6).Complications
The overall morbidity was 20.6% and not significantly
different between the two groups (18.8% vs. 22.2%, P =
0.704). Surgical and non-surgical complications are listed
in Table 7. Gastrointestinal motility disorders and surgi-
cal site infection were the most common complications.
Postoperative hemorrhage was more common in the
neoadjuvant group, whereas anastomotic leakage and
pulmonary problems were more common in the adju-
vant group. Pancreatic fistulae or abdominal abscesses
were not observed in either group. No patients required
reoperation and none of our patients died.
The overall median postoperative stay in the hospital
was 11 days in both groups (P = 0.920). For patients suffer-
ing complications, the mean postoperative stay in the
hospital was 15 days in the neoadjuvant group and 17 days
in the adjuvant group (P = 0.503). A postoperative stay
was much shorter if complications did not occur.
Discussion
The prevalence of postoperative complications after neo-
adjuvant chemotherapy has been reported to range from
10% to 46% and is based on the experience of the oper-
ating surgeon, multi-visceral resections, extended lymph
node dissections, different regimens, and elderly patients
with comorbidities [8,23-25]. As for neoadjuvant treat-
ments, some surgeons still believe that preoperative
chemotherapy may induce many early complications
after D2 surgery for locally advanced GC. Studies asses-
sing the impact of the SOX regimen as neoadjuvant
chemotherapy for AJCC stage II–III GC on surgical
morbidity and mortality are also lacking. Therefore, the
assessment on the safety of SOX neoadjuvant chemo-
therapy for locally advanced GC is essential.
In the present study, the prevalence of postoperative
morbidity in the neoadjuvant group was 18.8%. This re-
sult is in accordance with reports on the prevalence of
complications in patients who received D2 surgery with-
out preoperative chemotherapy [26-28]. Those data were
comparable to our results, in which postoperative mor-
bidity was seen in 17.9–29.4% of subjects. Relaparotomy
for surgical complications was necessary in the Dutch
gastric cancer trial [29]. Anastomotic leakage and pan-
creatic fistulae were the most common complications
for reoperations. Fortunately, no patient in the current
series underwent reoperations. Pancreatic fistulae were
not seen in the study. The single leakage was managed
by jejunal feedings, nasogastric tube, abdominal tube
drainage, and antibiotics. Pancreatic fistulae and anasto-
motic leakage should be observed frequently for D3 sur-
gery or multi-visceral resections. These results could be
attributed to modern surgical devices, experienced
surgeons, and prophylactic application of octreotide
acetate after D2 surgery. Infection at the incision site and
Table 6 Pathological results
Neoadjuvant (n = 80) Adjuvant (n = 90) P
Clinical/pathological tumor stage 0.323/<0.001
T0 0 (0%)/12 (15.0%) 0 (0%)/0 (0%)
T1 4 (5.0%)/9 (11.2%) 1 (1.1%)/1 (1.1%)
T2 7 (8.8%)/24 (30.0%) 10 (11.1%)/8 (8.9%)
T3 16 (20.0%)/15 (18.8%) 13 (14.4%)/16 (17.8%)
T4 53 (66.3%)/20 (25.0%) 66 (73.4%)/65 (72.2%)
Nodal status <0.001
N0 47 (58.8%) 13 (14.4%)
N1 (one to two nodes involved) 13 (16.3%) 20 (22.2%)
N2 (three to six nodes involved) 11 (13.8%) 25 (27.8%)
N3 (more than seven nodes involved) 9 (11.3%) 32 (35.6%)
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were observed frequently in the present study, but these
complications are minor and managed easily. For surgical
site infections, the bacteria need to be found, drug suscepti-
bility test has to be conducted, antibiotics need to be






PHS (days) 11 (7–33) 11 (5–51) 0.920a
PHS with complications (days) 15 17 0.503b
PHS without complications (days) 11 11 0.972a
Patients with complications 15 (18.8%) 20 (22.2%) 0.704
Non-surgical complications
Pneumonia 1 (1.3%) 3 (3.3%) 0.623
Pleural effusion 0 (0.0%) 2 (2.2%) 0.499
Gastrointestinal motility disorders 3 (3.8%) 3 (3.3%) 1.000
Thrombosis 1 (1.3%) 1 (1.1%) 1.000
Renal dysfunction 1 (1.3%) 1 (1.1%) 1.000
Catheter-related sepsis 1 (1.3%) 0 (0.0%) 0.471
Other (urinary,
thrombocytopenia)
1 (1.3%) 4 (4.4%) 0.372
Surgical complications
Anastomotic leakage 0 (0.0%) 2 (2.2%) 0.499
Surgical site infection 5 (6.2%) 6 (6.7%) 1.000
Postoperative hemorrhage 3 (3.8%) 1 (1.1%) 0.343
Wound dehiscence 0 (0.0%) 2 (2.2%) 0.499
Lymphorrhea 2 (2.5%) 1 (1.1%) 0.602
Ileus 0 (0.0%) 1 (1.1%) 1.000
Biliary fistula 1 (1.3%) 0 (0.0%) 0.471
PHS postoperative hospital stay. aStatistical analyses by the Mann–Whitney
U test due to non-normal distribution in one or both groups; bstatistical analyses
by the Student’s t test due to a normal distribution in both groups.postoperative hemorrhage, adequate blood transfusion
and hemocoagulase were essential and effective. There-
fore, we agree with the opinion that complications should
be managed conservatively and reexploration reserved for
patients whose conservative treatment is failed [30].
Multi-visceral resections, especially splenectomy and distal
pancreatectomy, were rarely needed. The Dutch trial had
reported that extended lymphadenectomy combined with
multi-visceral resection should be limited due to the in-
creased risk of surgery-related mortality and morbidity
[29]. If the tumor directly extended to the spleen, trans-
verse colon, or tail of pancreas, multi-visceral resections
need to be performed to achieve a high R0 rate. In this
study, the low rate of deaths and complications may be
associated with limited multi-visceral resections. In the
MAGIC trial, the prevalence of morbidity in the chemo-
therapy group was 45.7% [8]. The SOX regimen is less
toxic than the triplet regimen, so surgical morbidity does
not seem to increase even after D2 lymphadenectomy.
Because of fibrosis and tissue edema resulting from
chemotherapy, D2 lymphadenectomy after neoadjuvant
chemotherapy seemed to be more risky than D2 lymph-
adenectomy without preoperative treatment. Operative
hemorrhage should be easily induced by fibrosis and tissue
edema, although an ultrasonic knife plays an important
role in hemostasis. Therefore, more operative blood loss
can be seen in the neoadjuvant group. Indirectly, it took
harder and longer to stop the bleeding (Table 5). However,
no deaths occurred during and after D2 surgery upon neo-
adjuvant chemotherapy with the SOX regimen. In a phase
II trial of neoadjuvant chemotherapy with the SP regimen,
surgical mortality was not observed [24]. Another phase II
trial was conducted to assess the safety of neoadjuvant
chemotherapy with irinotecan and cisplatin before D3 re-
section but was terminated, and the prevalence of surgical
mortality was nearly 2.0% [31].
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far. We arranged the courses based on MAGIC, FFCD,
and COMPASS trials which demonstrated that three or
four neoadjuvant courses could achieve a better progno-
sis [8,9,32]. Due to the main advantage of neoadjuvant
chemotherapy which is good tolerance of preoperative
treatment, patients receiving more than two cycles of
chemotherapy did not have grade 3 or 4 adverse out-
comes. Less toxic oxaliplatin may also contribute to the
result [16]. Thus, if the patients were not strongly
willing to perform the operation immediately, we
recommended three or four courses to them.
Clinical responses in 31 patients were evaluated as SD or
PD when the criteria were analyzed after two cycles. In
these patients, the responses of 13 patients who received
two cycles were not sensitive to the SOX regimen. Thus,
D2 surgery was performed for them immediately. On the
other hand, the response of the other 18 patients was mildly
sensitive to SOX chemotherapy but not evaluated as PR
after two courses. Therefore, following the recommended
number of courses used by the MAGIC trial, we conducted
one more cycle for them. In these 18 patients, the response
of a few patients was assessed as PR before surgery because
of relatively adequate courses. Disease control rate was
97.5%. Thus, we considered that this treatment protocol
did not worsen the situation in these patients.
The present study demonstrated a relatively high clin-
ical RR of 68.8%, which was virtually the same as that
observed for tumor downstaging. In three phase II trials
using the SOX regimen against advanced GC, the clin-
ical RRs were 55.3%, 59.0%, and 53.7% [14,33,34]. The
RR was higher because 67 (83.8%) patients received
three or four cycles of preoperative chemotherapy in the
present study. The COMPASS trial proved that patients
benefitted from adequate courses of neoadjuvant chemo-
therapy, which was consistent with this study [32].
All patients received D2 surgical resections with good
tolerance of SOX neoadjuvant chemotherapy, while Kochi
reported that 88% eligible patients underwent curative sur-
gery with SP regimen as neoadjuvant chemotherapy [35].
This result may contribute to a less toxic SOX regimen
because no patient had grade 3 or 4 toxicities in this
study.
Before the initiation of preoperative chemotherapy, the
clinical T staging showed no significant difference in the
two groups (P = 0.323). However, after the patients
underwent D2 resection, the pathological results demon-
strated that the proportion of stage T3 and T4 tumors in
the neoadjuvant group was smaller than in the adjuvant
group. There was also less metastasis of lymph nodes in
the neoadjuvant group than in the adjuvant group. The
downstaging rate and pathological response were con-
sistent with clinical response in the neoadjuvant group.
Furthermore, the tumors were obviously shrunk afterneoadjuvant chemotherapy. These results were attrib-
uted to the efficacy of SOX neoadjuvant chemotherapy.
A pCR is associated with prognosis, so the primary end-
point was pCR in this study [36]. Thus, all the patients re-
ceived D2 surgery. In the neoadjuvant group, only two
patients were performed the surgery immediately when the
assessment was PD. Another major finding of the present
study was a high pCR of 12.5% after neoadjuvant chemo-
therapy with the SOX regimen. Several studies have failed
to show that preoperative chemotherapy can elicit such
high pCRs [8,9,23-25,31,32]. Furthermore, in the ten pa-
tients who achieved a pCR, nine patients received three or
four cycles of the SOX regimen, which was in accordance
with the results of the COMPASS trial [32]. These results
suggested that the SOX regimen was a promising treatment
to achieve high pCRs with an adequate number of courses.
This retrospective study compared the results of two
groups at the same institution. There was a good balance
in each group in terms of the characteristics of patients
and tumors, but patients were enrolled based on their
preference and treated with at least two courses depending
on the sensitivity to neoadjuvant chemotherapy. Surgeon
experience and the interpretations of the pathologist could
lead to a confounding bias, so the procedures were carried
out by the same team of surgeons, and resections assessed
by the same experienced pathologist. This trial did not
include node-negative advanced gastric cancer in the
neoadjuvant group, which may be attributed to inevitably
overdiagnosed preoperative staging and the relatively crit-
ical illness in our center. In the present analysis, we mainly
focused on the patients with lymph node metastasis stage
II–III gastric cancer.
Conclusions
Here, we showed that neoadjuvant chemotherapy with at
least two cycles of the SOX regimen could induce a rela-
tively high number of pathological CRs without increasing
the prevalence of morbidity and mortality compared with
D2 resection alone. In this regard, neoadjuvant chemother-
apy with the SOX regimen followed by gastrectomy with
D2 resection is an effective and feasible candidate for treat-
ing AJCC stage II/III GC. A prospective RCT to evaluate
the efficacy and survival benefits of neoadjuvant chemo-
therapy with the SOX regimen for locally advanced GC has
been launched in China (RESONANCE; clinical trial num-
ber NCT01583361).
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